|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 10 (November 15), 1999:
pp. 3334-3339
A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration
Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's
Lymphoma
Petri Salven,
Lasse Teerenhovi, and
Heikki Joensuu
From the Department of Oncology, Helsinki University Central
Hospital, Helsinki, Finland.
Basic fibroblast growth factor (bFGF) is a secreted multifunctional
cytokine and a potent stimulator of angiogenesis in vivo. Elevated bFGF concentrations have been detected in the serum and urine of cancer patients. We measured bFGF by enzyme-linked
immunosorbent assay from sera taken from 160 non-Hodgkin's lymphoma
(NHL) patients before treatment and stored at  20°C. The patients
had been observed for at least 5 years or until death. Serum bFGF
concentrations (S-bFGF) ranged from undetectable to 34.7 pg/mL (median,
3.3 pg/mL). S-bFGF was detectable with a similar frequency in all
subtypes of NHL. A high pretreatment S-bFGF was associated with poor
overall survival. The 5-year survival rate of the patients within the highest quartile of S-bFGF concentrations (S-bFGF = 5.5 pg/mL) was
only 39%, in contrast to a 60% survival rate of the patients with
lower S-bFGF (P = .019). A high S-bFGF (within the highest quartile) was associated with poor outcome also in large-cell diffuse
and immunoblastic lymphomas (5-year survival rates of 28% v
56%, respectively; P = .027), which was the largest
histologic subgroup (n = 66) within the series. In multivariate
analyses, S-bFGF was an independent prognostic factor, both when the
highest quartile was used as a cut-off value (P = .0079) and when S-bFGF and the other parameters were entered into the
model as continuous variables (P = .024). In the multivariate
analyses, S-bFGF had a noticeably stronger prognostic value than serum
lactate dehydrogenase and the number of extranodal tumor sites, both of
which are currently included as components in the International
Prognostic Index.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis
Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962
Clin. Cancer Res.,
December 1, 2006;
12(23):
6978 - 6984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Buckstein, R. S. Kerbel, Y. Shaked, R. Nayar, C. Foden, R. Turner, C. R. Lee, D. Taylor, L. Zhang, S. Man, et al.
High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
September 1, 2006;
12(17):
5190 - 5198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al.
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone
PNAS,
July 26, 2005;
102(30):
10628 - 10633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Tebben, K. R. Kalli, W. A. Cliby, L. C. Hartmann, J. P. Grande, R. J. Singh, and R. Kumar
Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors
Mayo Clin. Proc.,
June 1, 2005;
80(6):
745 - 751.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Bieker, T. Padro, J. Kramer, M. Steins, T. Kessler, S. Retzlaff, F. Herrera, J. Kienast, W. E. Berdel, and R. M. Mesters
Overexpression of Basic Fibroblast Growth Factor and Autocrine Stimulation in Acute Myeloid Leukemia
Cancer Res.,
November 1, 2003;
63(21):
7241 - 7246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Schuch, M. Machluf, G. Bartsch Jr, M. Nomi, H. Richard, A. Atala, and S. Soker
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo
Blood,
December 15, 2002;
100(13):
4622 - 4628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven
High Pretreatment Serum Concentration of Basic Fibroblast Growth Factor Is a Predictor of Poor Prognosis in Small Cell Lung Cancer
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2002;
11(11):
1492 - 1495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa
Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer
Cancer Res.,
September 15, 2002;
62(18):
5210 - 5217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood,
May 1, 2002;
99(9):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Neben, T. Moehler, G. Egerer, A. Kraemer, J. Hillengass, A. Benner, A. D. Ho, and H. Goldschmidt
High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma
Clin. Cancer Res.,
September 1, 2001;
7(9):
2675 - 2681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
J. Clin. Oncol.,
February 15, 2001;
19(4):
1207 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Murphy, M. Limoges, F. Dodd, R. T. M. Boudreau, and C. K. L. Too
Fibroblast Growth Factor-2 Stimulates Endothelial Nitric Oxide Synthase Expression and Inhibits Apoptosis by a Nitric Oxide-Dependent Pathway in Nb2 Lymphoma Cells
Endocrinology,
January 1, 2001;
142(1):
81 - 88.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients
Blood,
December 1, 2000;
96(12):
3712 - 3718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bertolini, L. Fusetti, P. Mancuso, A. Gobbi, C. Corsini, P. F. Ferrucci, G. Martinelli, and G. Pruneri
Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
Blood,
July 1, 2000;
96(1):
282 - 287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
